TY - JOUR T1 - Esmya (ulipristal acetate) - safety update JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 50 LP - 50 DO - 10.1136/dtb.2018.5.0616 VL - 56 IS - 5 A2 - , Y1 - 2018/05/01 UR - http://dtb.bmj.com/content/56/5/50.1.abstract N2 - The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced temporary safety measures for Esmya (ulipristal acetate) while an EU-wide review investigates the link between the medicine and serious liver injury, including four cases that required liver transplantation.1 Clinicians should not initiate or re-start treatment and should monitor liver function in current and recent users.Esmya is licensed for use in adult women of reproductive age for pre-operative treatment and for intermittent treatment of moderate to severe symptoms of … ER -